Gennova completes Phase 2 and 3 trials of mRNA jab by January 2022

by

Excerpt

By the end of January next year, Gennova Biopharmaceuticals, a subsidiary of Emcure, a Pune-based pharmaceutical business that develops mRNACovid vaccines, will have completed Phase 2/3 studies and will apply to Indian drug regulators for an emergency use authorisation.

Article Summary

In 35 centres throughout India, Gennova has started Phase 2 and Phase 3 clinical trials of the mRNA-based vaccine HGCO19.

Unlike early COVID-19 vaccines like Covaxin and Covishield (AstraZeneca vaccine), which were evaluated against placebo in Phase 3, Gennova’s mRNA vaccine uses Covishield as a comparison, allowing testing to be completed faster.

CDSCO evaluated the safety and immunogenicity of the company’s mid-Phase 1 clinical trial results.

Unlike other mRNA vaccines that require temperatures above -20 ° C, Gennova’s mRNA vaccine is based on lyophilization technology, which allows storage at 2-8 ° C.

Emcure’s founder and CEO, Satish Mehta, said the company is also looking at the possibility of developing tuberculosis vaccines using the mRNA platform.

In addition to the COVID-19 vaccine, Gennova is employing the mRNA platform to develop vaccinations for deer, rabies, and herpes zoster.

Source: Gennova Biopharmaceuticals Ltd. , 2021

Comments

Leave A Comment

Leave a Reply

Your email address will not be published.

bag